2024年 大手製薬企業による50件以上のプレゼンテーション

Augmenting Antibody-Drug Discovery with Deep Screening and Machine Learning
Christopher Wassif, PhD, Director, Molecular Engineering & Antibody Technologies, AstraZeneca

Chimeric Antigens Displaying GPR65 Extracellular Loops for Antibody Discovery
Cécile Galmiche, PhD, Senior Scientist, Antibody Discovery, UCB

Considerations for the Successful Development of Targeted Radiotherapies
Urs B. Hagemann, PhD, Head, Targeted Radiopharmaceuticals, Research & Early Development Oncology, Bayer AG

Exploring Non-Canonical Disulfide in Rabbit Antibody: Developability, Structure, and Engineering
Wei-Ching Liang, PhD, Staff Scientist, Antibody Engineering, Genentech, Inc.

Development of a Novel Antibody-Based Oral Factor VIII Mimetic Drug Candidate (Inno8)
Jais R. Bjelke, PhD, Principal Scientist, Global Research, Novo Nordisk AS

Enhancing Antibody Language Models with Structural Information
Jinwoo Leem, PhD, Associate Director, Data Science, Alchemab Therapeutics

Chain-Exchange and Split-Protein Technologies for the Generation of Targeted Antibody and Cytokine Prodrugs
Vedran Vasic, PhD, Scientist, Pharma Research and Early Development (pRED), Roche

Overcoming the Challenges with Raising Antibodies against STEAP2 Extracellular Domains for Targeted CAR T Cell Therapy
Dewald van Dyk, PhD, Associate Director, Biologics Engineering, AstraZeneca Pharmaceuticals LP

First-in-Human (FIH) Dose Selection for Biologic Modalities
Celine Amara, Project Expert, DMPK, Sanofi

Comparative Evaluation of Antigen Format Performance with Different Antibody Platforms
Corey Smith, PhD, Principal Research Scientist, Global Biologics Protein Science, AbbVie

Discovery Strategies for Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Trevor Wilkinson, PhD, Director, Biologics Engineering, AstraZeneca

An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T Cell Function and Antitumour Immunity
Javier Chaparro-Riggers, PhD, Executive Director, BioMedicine Design, Pfizer Inc.

Bispecific and Trispecific T Cell Engagers for the Treatment of Hematological Malignancies
Ulrike Philippar, PhD, Senior Director & Head, Oncology & Discovery Hematological Malignancies, Johnson & Johnson Innovative Medicine

Preclinical Development of DuoBody-CD3-H101GxB7H4, a Novel CD3 Bispecific Antibody for the Treatment of Solid Cancers
Marije Overdijk, PhD, Director, Team Lead Translational Research, Genmab

High-Throughput Bispecific Antibody Production & Potential Applications within Discovery Workflows
Charlotte H. Coles, PhD, Team Leader, GSK

The Present and Future of Bispecific Antibodies for Cancer Therapy
Christian Klein, PhD, Head, Oncology Programs and Department Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED

Advancing Cancer Immunotherapy: Next-Generation T Cell Engagers Targeting CLDN6 via CD3/CD137 Binding
Shinya Ishii, Senior Manager, Research Division, Chugai Pharmaceutical Co. Ltd.

Design Meets Biology-Engineering Multispecific Modalities with Potentially Improved TI
Yariv Mazor, PhD, Senior Director, R&D, Biologics Engineering, AstraZeneca

A FAP-Targeted LTBR-Agonistic Bispecific Antibody Modulating the Tumour Microenvironment to Induce the Formation of HEV-Rich Immune Niches and Enhance CPI Efficacy
Leo Kunz, PhD, Principal Scientist, Roche

Emerging Role of Neutrophils in Anti-Tumour Immunity
Rajkumar Noubade, PhD, Director, Oncology, Gilead Sciences

De-Risking in vivo PK Attributes of Therapeutic Antibody Lead Panels Using High-Throughput in vitro Approaches as Part of Early Drug Discovery and Human Dose Prediction Strategy
Jennifer Drew, Principal Investigator, GlaxoSmithKline

Assessing and Optimising Developability for Multispecifics and Antibody-Drug Conjugates
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA

Advancing Biotherapeutic Developability: Computational Strategies across Diverse Therapeutic Modalities
Goran Milicic, PhD, Senior Expert, Science & Technology, Novartis

In silico Developability for Biologics
Isabelle Sermadiras, Associate Principal Scientist, AstraZeneca

Insights from MAM Implementation at Roche/Genentech
Alexander Buettner, PhD, Senior Scientist, Pharma Technical Development, Roche

Unlocking the Power of Data: AbbVie's Digital Transformation Journey into CMC Biologics Development
Dana I. Filoti, PhD, Associate Director of Scientific Architecture, Development Sciences Data and Digital Strategy, Abbvie

Analytical Characterisation in ADC Discovery: Challenges & Approaches
Elizabeth Love, PhD, Scientific Leader, Antibody Drug Conjugate Platform, GSK

Development of Assay-Evaluating LINC Format of LINC-Ig
Shusuke Nambu, PhD, Analytical Development Department, Chugai Pharmaceutical Co. Ltd.

Comparison of Biosimilars and Innovative Biologics from an Analytical Perspective
Sasa Vrhovec Hartman, PhD, Senior Expert, Science & Technology R&D, Novartis Pharma Services Inc.

A Universal Tool for Stability Predictions of Biotherapeutics
Heloise Quillay, PhD, Principal Scientist and Team Leader, CMC Analytics, Sanofi

The Protein-Stabilising Capability of Surfactants against Agitation- and Surface-Induced Stresses
Supriyadi Hafiz, Senior Scientist, Liquid Formulation R&D, Merck Life Science KGaA

PS80 Oxidation Case Study: Impact of Tubing Material on Stability and Filling Accuracy of Biologic Drug Product
Heloise Audat, Head, Formulation and Development Laboratory, Biologics Drug Product Development, Sanofi
Laetitia Poumarede, Drug Product Process Development Engineer, Sanofi

Evaluating High-Concentration Solution Dynamics of Therapeutic Proteins in Biologics Research and Development
Benjamin Weiche, PhD, Senior Scientist, Large Molecule Research, Biochemical & Analytical Research, Roche Innovation Center Munich

In silico Formulation Development for Protein-Based Therapeutics
Giuseppe L. Licari, PhD, Lead Scientist, Computational Structural Biology, Global Drug Product Development-BDC, Merck Serono SA

Learning from the Past: Use of in silico Models to Predict Physico-Chemical Profiles of Biotherapeutics
Kannan Sankar, PhD, Senior Expert I, Data Science & Bioinformatics, Novartis Institutes for Biomedical Research Inc.

Data Generation and Modelling in Combined Simulation and High-Throughput Screening for Biotherapeutic Formulation Development
Maurizio Baldassarre, PhD, Associate Director & Head, Early Phase Drug Product Development, Merck

Using Machine Learning to Predict Recombinant Protein Expression
Sarah Caswell, PhD, Associate Principal Scientist, AstraZeneca

Tailor-Made CHO Manufacturing Cell Lines Using Artificial Intronic miRNAs
David Ausländer, PhD, Senior Principal Scientist & Group Head, Biologics Research Center, Novartis AG

Mammalian Expression of Difficult-to-Express Proteins: Insights into BiTE Molecule Production Bottlenecks
Benedikt Greck, Graduate Student, Large Molecular Discovery & Research Data Science, Amgen Research Munich GmbH

Customisable Protein Expression
Marina Fedorova, PhD, Scientific Investigator, Protein and Cellular Science, GSK

Harnessing the Power of dPCR and NGS-Based Tools for Advanced Genetic Screening in Cell-Line Development
Daniel Heinzelmann, Process Expert, Cell Line Development, Boehringer Ingelheim Pharma GmbH & Co. KG

Using Stable Producer Cell Lines for Manufacturing of Lentiviral Vectors
Jessica Vogel, Associate Scientist, BPD VVPD, CSL Innovation GmbH

A Generic Approach for Miniaturised Unbiased Bispecific Antibody Screening via Automated Intein- or cFAE-Based Workflows
Achim Doerner, PhD, Associate Director, Antibody Discovery & Protein Engineering, Merck Healthcare KGaA

Accelerating Drug Discovery: High-Throughput Semi-Automated Expression Platform for Antibody Lead Generation
Lucy Holt, PhD, Director, Large Molecule Discovery, GSK

High-Throughput Analytics: Shaping Data-Driven Decisions in Biopharmaceutical Development
Giulia Lambiase, PhD, Senior Scientist, Biopharmaceutical Development, AstraZeneca

Scalable Active Learning for Therapeutic Antibody Design
Nathan Frey, PhD, Senior Machine Learning Scientist, Prescient Design, a Genentech Company

IBM Collaboration to Advance Generative AI and Foundation Models for Therapeutic Antibody Development
Kausheek Nandy, Digital Transformation-Research, Boehringer Ingelheim Pharmaceuticals Inc.

Pioneering Data-Driven Strategies in de novo Nanobody Design
Roberto Spreafico, PhD, Director, Discovery Data Science, Genmab

Antibody CDR Design by Ensembling Inverse Folding with Protein Language Models
Diego Del Alamo, PhD, Computational Biologist, GSK

Improved Antibody-Antigen Interaction Prediction Using Inverse Folding Latent Representations
Paolo Marcatili, PhD, Director, Antibody Design, Novo Nordisk

Preclinical Efficacy and Safety of a Novel Anti-CEA TOPO1i ADC M9140
Min Shan, PhD, Medicinal Chemist, Targeted Therapeutics, Merck KGaA

CEACAM5C, a Novel Topoisomerase I Inhibitor Antibody-Drug Conjugate Targeting CEACAM5 with High Preclinical Anti-Tumour Activity in CRC, PDAC, GC, and Lung Cancer Tumour Models
Yves Baudat, Senior Scientist, Immuno Oncology, Sanofi

Format Matters for ADCs: Generation of Binder-Format-Payload Conjugate Matrices by Antibody Chain Exchange
Ulrich Brinkmann, PhD, Expert Scientist, Pharma Research & Early Development, Roche Innovation Center, Munich

* As of 18 June. Please see individual agenda pages for most up-to-date agenda.